Methods of treating psoriasis using IL-17 Receptor A antibodies
View Patent ↗The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
1. A method of treating psoriasis, comprising administering to a patient having psoriasis a composition comprising an antibody selected from the group consisting of:
a. an isolated antibody, comprising
a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14; and
b. an isolated antibody, comprising
a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, a heavy chain CDR3 comprising SEQ ID NO:148,
wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
2. The method of claim 1 further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
3. The method of claim 1 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a diabody;
h. a triabody;
i. a tetrabody;
j. a Fab fragment;
k. a F(ab′)2 fragment;
l. an IgD antibody;
m. an IgE antibody;
n. an IgM antibody;
o. an IgG1 antibody;
p. an IgG2 antibody;
q. an IgG3 antibody; and
r. an IgG4 antibody.
4. The method of claim 1 , wherein said composition is a pharmaceutical composition.
5. A method of treating psoriasis, comprising administering to a patient having psoriasis a composition comprising an isolated antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
6. The method of claim 5 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
7. The method of claim 5 , wherein said composition is a pharmaceutical composition.
8. The method of claim 5 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a diabody;
h. a triabody;
i. a tetrabody;
j. a Fab fragment;
k. a F(ab′)2 fragment;
l. an IgD antibody;
m. an IgE antibody;
n. an IgM antibody;
o. an IgG1 antibody;
p. an IgG2 antibody;
q. an IgG3 antibody; and
r. an IgG4 antibody.
9. The method of claim 5 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a Fab fragment;
h. a F(ab′)2 fragment;
i. an IgG1 antibody; and
j. an IgG2 antibody.
10. The method of claim 5 , wherein said antibody is a human antibody.
11. The method of claim 5 , wherein said antibody is a monoclonal antibody.
12. The method of claim 5 , wherein said antibody is a human monoclonal antibody.
13. The method of claim 5 , wherein said antibody is a human IgG2 monoclonal antibody.
14. A method of treating psoriasis, comprising administering to a patient having psoriasis a composition comprising an isolated antibody comprising a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
15. The method of claim 14 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
16. The method of claim 14 , wherein said composition is a pharmaceutical composition.
17. The method of claim 14 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a diabody;
h. a triabody;
i. a tetrabody;
j. a Fab fragment;
k. a F(ab′)2 fragment;
l. an IgD antibody;
m. an IgE antibody;
n. an IgM antibody;
o. an IgG1 antibody;
p. an IgG2 antibody;
q. an IgG3 antibody; and
r. an IgG4 antibody.
18. The method of claim 14 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a Fab fragment;
h. a F(ab′)2 fragment;
i. an IgG1 antibody; and
j. an IgG2 antibody.
19. The method of claim 14 , wherein said antibody is a human antibody.
20. The method of claim 14 , wherein said antibody is a monoclonal antibody.
21. The method of claim 14 , wherein said antibody is a human monoclonal antibody.
22. The method of claim 14 , wherein said antibody is a human IgG2 monoclonal antibody.